Ongoing monitoring and treatment of RA patients’ mental health is important and may impact long-term RA outcomes.
Dinesh Khanna, MD, MSc, discusses results of the open-label portion of a trial evaluating the safety and efficacy of placebo-treated patients with systemic sclerosis who were switched to received open-label tocilizumab.
A randomized-control trial found that mind-body skills training improved depressive symptoms in patients with SLE.
John H. Stone, MD, MPH, discusses results from a phase 3, double-blind, randomized, controlled trial evaluating the efficacy of tocilizumab for the treatment of giant cell arteritis.
Gerd Burmester, MD,discusses results from the SARIL-RA-MONARCH trial.
Recognizing depression in PsA is important because psychological well-being may contribute to disease activity in PsA.
Sarah Taber, MD, briefly reviews her ongoing research on genetic drivers of localized scleroderma in pediatric patients.
Levels of depression and anxiety varied by disease. Special attention should be paid to patients with fibromyalgia, osteoarthritis, and rheumatoid arthritis.
Kenneth Saag, MD, discusses new pooled safety data for lesinurad for the treatment of gout.
Secukinumab treatment was associated with higher ASAS 20 response rates at weeks 16, 24, and 52 and ASAS 40 at weeks 24 and 52 compared with treatment with adalimumab.